Elsevier

The Lancet

Volume 370, Issue 9581, 7–13 July 2007, Pages 89-93
The Lancet

Viewpoint
Pre-exposure prophylaxis for HIV infection: what if it works?

https://doi.org/10.1016/S0140-6736(07)61053-8Get rights and content

Section snippets

Pre-exposure prophylaxis

Disease prevention by prophylactic drugs is standard practice in travellers to malaria-endemic countries and for other infections such as Pneumocystis jirovecii in HIV infection. Various studies11, 12, 13, 14 show that antiretroviral treatment given at or shortly after an exposure can substantially reduce HIV transmission: prompt treatment clearly increases effectiveness.15 This observation led to the hypothesis that transmission could be decreased further if treatment was delivered before

Drug toxicity and viral resistance

Tenofovir (and tenofovir and emtricitabine) has a good safety profile and infrequent side-effects; the most common side-effects are gastrointestinal discomfort, dizziness, headache, and rash. Less than 1% of patients with HIV taking tenofovir in clinical trials had serious drug-related adverse events such as acute renal failure, Fanconi's syndrome resulting in severe hypophosphataemia, decreases in bone-mineral density, and rarely, lactic acidosis.22 Tenofovir plus emtricitabine has the same

Increased risky behaviours

Mathematical modelling of HIV transmission by people taking antiretroviral drugs suggests that reduction or reversal of any benefits could result from a small increase in risky sexual behaviour.26, 27 Although pre-exposure prophylaxis might greatly reduce HIV transmission, this effect could diminish if people taking such prophylaxis increase their risky behaviour. Moreover, HIV prophylaxis offers no protection against other sexually transmitted infections.

Present trials should provide data for

Ethics

The possibility of pre-exposure prophylaxis for HIV raises important ethical questions such as: what are the obligations of governments and industry to provide such prophylaxis? How should resources be distributed between research, treatment, counselling, testing, primary prevention, pre-exposure prophylaxis, and post-exposure prophylaxis? Who should have priority for prophylaxis? These types of issues arise in many health-care settings; however stigma associated with HIV poses particular

Public-health issues

Mathematical models of pre-exposure prophylaxis35 and topical anti-HIV microbicides,36, 37, 38 suggest that even a partially effective product could avert many infections. The trials of pre-exposure prophylaxis will provide important safety and efficacy data for prevention of HIV transmission by injecting drug users and through sexual intercourse. However, even after these trials conclude many information gaps will remain. Perhaps most important is that not all groups at risk are included. For

Steps to take today

In August, 2006, the Global HIV Prevention Working Group, an international panel of more than 50 experts on HIV and AIDS, was convened by the Bill and Melinda Gates Foundation to discuss HIV-prevention research, and released a report about factors necessary for enabling access to new HIV-prevention technology. These factors include early commitment of resources from donors, coordination between governments and regulatory agencies, and planning of guidelines for use.39 Although the first results

First page preview

First page preview
Click to open first page preview

References (40)

  • J Van de Wijgert et al.

    Microbicides to prevent heterosexual transmission of HIV: ten years down the road

    BETA

    (2002)
  • Z Rosenberg

    Microbicide Research, a promising prevention strategy for HIV/AIDS. Can it save women's lives?

  • EM Connor et al.

    Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

    N Engl J Med

    (1994)
  • DM Cardo et al.

    A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group

    N Engl J Med

    (1997)
  • CC Tsai et al.

    Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment

    J Virol

    (1998)
  • KK Van Rompay et al.

    Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection

    J Infect Dis

    (2001)
  • S Subbarao et al.

    Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against simian human immunodeficiency virus infection in macaques given multiple virus challenges

    J Infect Dis

    (2006)
  • J Garcia-Lerma et al.

    Prevention of rectal SHIV transmission in macaques by tenofovir/FTC combination. Presented at: 13th Conference on Retroviruses and Opportunistic Infections Feb 5–8, 2006

  • Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase...
  • J Cohen

    Protect or Disinhibit?

    New York Times Magazine (New York)

    (Jan 22, 2006)
  • Cited by (0)

    View full text